Impact of Body Mass Index on Surgical and Oncological Outcomes in Laparoscopic Total Mesorectal Excision for Locally Advanced Rectal Cancer after Neoadjuvant 5-Fluorouracil-Based Chemoradiotherapy

Table 4

Oncological clearance between nonobese and obese groups in locally advanced rectal cancer patients after nCRT.

Characteristics	BMI < 25 ()	BMI ≥ 25 ()	value
Length of resection margin (cm)
Proximal	14.9 ± 3.5	14.8 ± 1.9	0.864
Distal	3.2 ± 1.2	3.0 ± 1.1	0.172
CRM involvement	3 (1.2)	2 (3.2)	0.266
Tumor clearance			0.382
R0	242 (97.2)	59 (93.7)
R1	4 (1.6)	2 (3.2)
R2	3 (1.2)	2 (3.2)
No. of lymph node retrieved	12.7 ± 8.2	11.4 ± 4.8	0.107
Lymph node ratio	0.08 (0–0.86)	0.04 (0–0.47)	0.278
ypUICC stages			0.617
0	48 (18.3)	10 (15.9)
I	59 (23.7)	17 (27.0)
II	68 (27.3)	21 (33.3)
III	74 (29.7)	15 (23.8)
Tumor grade			0.196
G1 + G2	214 (85.9)	50 (79.4)
G3 + GX	35 (14.1)	13 (20.6)
pCR	48 (19.3)	10 (15.9)	0.535
RCRG			0.221
I	137 (55.0)	28 (44.4)
II	89 (35.7)	30 (47.6)
III	23 (9.2)	5 (7.9)

Data are expressed as number (%) or as median ± standard deviation, where appropriate.Data are expressed as median (range) and analyzed with the Mann–Whitney U test. nCRT: neoadjuvant chemoradiotherapy; CRM: circumferential resection margin; pCR: pathological complete response; RCRG: rectal cancer regression grade: RCRG 1, sterilization or only microscopic foci of adenocarcinoma remaining, with marked fibrosis; RCRG 2, marked fibrosis but macroscopic disease present; RCRG 3, little or no fibrosis, with abundant macroscopic disease.